Literature DB >> 28410299

Antigen Discovery and Therapeutic Targeting in Hematologic Malignancies.

David A Braun1, Catherine J Wu.   

Abstract

Historically, immune-based therapies have played a leading role in the treatment of hematologic malignancies, with the efficacy of stem cell transplantation largely attributable to donor immunity against malignant cells. As new and more targeted immunotherapies have developed, their role in the treatment of hematologic malignancies is evolving and expanding. Herein, we discuss approaches for antigen discovery and review known and novel tumor antigens in hematologic malignancies. We further explore the role of established and investigational immunotherapies in hematologic malignancies, with a focus on personalization of treatment modalities such as cancer vaccines and adoptive cell therapy. Finally, we identify areas of active investigation and development. Immunotherapy is at an exciting crossroads for the treatment of hematologic malignancies, with further investigation aimed at producing effective, targeted immune therapies that maximize antitumor effects while minimizing toxicity.

Entities:  

Mesh:

Substances:

Year:  2017        PMID: 28410299      PMCID: PMC5856170          DOI: 10.1097/PPO.0000000000000257

Source DB:  PubMed          Journal:  Cancer J        ISSN: 1528-9117            Impact factor:   3.360


  179 in total

1.  Ipilimumab for Patients with Relapse after Allogeneic Transplantation.

Authors:  Matthew S Davids; Haesook T Kim; Pavan Bachireddy; Caitlin Costello; Rebecca Liguori; Alexandra Savell; Alexander P Lukez; David Avigan; Yi-Bin Chen; Peter McSweeney; Nicole R LeBoeuf; Michael S Rooney; Michaela Bowden; Chensheng W Zhou; Scott R Granter; Jason L Hornick; Scott J Rodig; Masahiro Hirakawa; Mariano Severgnini; F Stephen Hodi; Catherine J Wu; Vincent T Ho; Corey Cutler; John Koreth; Edwin P Alyea; Joseph H Antin; Philippe Armand; Howard Streicher; Edward D Ball; Jerome Ritz; Asad Bashey; Robert J Soiffer
Journal:  N Engl J Med       Date:  2016-07-14       Impact factor: 91.245

2.  Expression of tumor-associated antigens in acute myeloid leukemia: Implications for specific immunotherapeutic approaches.

Authors:  Jochen Greiner; Michael Schmitt; Li Li; Krzysztof Giannopoulos; Katrin Bosch; Anita Schmitt; Konstanze Dohner; Richard F Schlenk; Jonathan R Pollack; Hartmut Dohner; Lars Bullinger
Journal:  Blood       Date:  2006-08-24       Impact factor: 22.113

3.  Donor leukocyte infusions in 140 patients with relapsed malignancy after allogeneic bone marrow transplantation.

Authors:  R H Collins; O Shpilberg; W R Drobyski; D L Porter; S Giralt; R Champlin; S A Goodman; S N Wolff; W Hu; C Verfaillie; A List; W Dalton; N Ognoskie; A Chetrit; J H Antin; J Nemunaitis
Journal:  J Clin Oncol       Date:  1997-02       Impact factor: 44.544

4.  One hundred patients with acute leukemia treated by chemotherapy, total body irradiation, and allogeneic marrow transplantation.

Authors:  E D Thomas; C D Buckner; M Banaji; R A Clift; A Fefer; N Flournoy; B W Goodell; R O Hickman; K G Lerner; P E Neiman; G E Sale; J E Sanders; J Singer; M Stevens; R Storb; P L Weiden
Journal:  Blood       Date:  1977-04       Impact factor: 22.113

5.  Predictive correlates of response to the anti-PD-L1 antibody MPDL3280A in cancer patients.

Authors:  Roy S Herbst; Jean-Charles Soria; Marcin Kowanetz; Gregg D Fine; Omid Hamid; Michael S Gordon; Jeffery A Sosman; David F McDermott; John D Powderly; Scott N Gettinger; Holbrook E K Kohrt; Leora Horn; Donald P Lawrence; Sandra Rost; Maya Leabman; Yuanyuan Xiao; Ahmad Mokatrin; Hartmut Koeppen; Priti S Hegde; Ira Mellman; Daniel S Chen; F Stephen Hodi
Journal:  Nature       Date:  2014-11-27       Impact factor: 49.962

6.  Receptor for hyaluronan acid-mediated motility (RHAMM) is a new immunogenic leukemia-associated antigen in acute and chronic myeloid leukemia.

Authors:  Jochen Greiner; Mark Ringhoffer; Masanori Taniguchi; Anita Schmitt; Dieter Kirchner; Gertraud Krähn; Volker Heilmann; Jürgen Gschwend; Lothar Bergmann; Hartmut Döhner; Michael Schmitt
Journal:  Exp Hematol       Date:  2002-09       Impact factor: 3.084

7.  Biologic activity of irradiated, autologous, GM-CSF-secreting leukemia cell vaccines early after allogeneic stem cell transplantation.

Authors:  Vincent T Ho; Matthew Vanneman; Haesook Kim; Tetsuro Sasada; Yoon Joong Kang; Mildred Pasek; Corey Cutler; John Koreth; Edwin Alyea; Stefanie Sarantopoulos; Joseph H Antin; Jerome Ritz; Christine Canning; Jeffery Kutok; Martin C Mihm; Glenn Dranoff; Robert Soiffer
Journal:  Proc Natl Acad Sci U S A       Date:  2009-08-26       Impact factor: 11.205

8.  Immune responses to RHAMM in patients with acute myeloid leukemia after chemotherapy and allogeneic stem cell transplantation.

Authors:  R Casalegno-Garduño; C Meier; A Schmitt; A Spitschak; I Hilgendorf; S Rohde; C Hirt; M Freund; B M Pützer; M Schmitt
Journal:  Clin Dev Immunol       Date:  2012-06-06

Review 9.  New antibody approaches to lymphoma therapy.

Authors:  Tejas Suresh; Lisa X Lee; Jitesh Joshi; Stefan K Barta
Journal:  J Hematol Oncol       Date:  2014-09-09       Impact factor: 17.388

10.  A nonapeptide encoded by human gene MAGE-1 is recognized on HLA-A1 by cytolytic T lymphocytes directed against tumor antigen MZ2-E.

Authors:  C Traversari; P van der Bruggen; I F Luescher; C Lurquin; P Chomez; A Van Pel; E De Plaen; A Amar-Costesec; T Boon
Journal:  J Exp Med       Date:  1992-11-01       Impact factor: 14.307

View more
  3 in total

Review 1.  Adoptive Immunotherapy with Antigen-Specific T Cells Expressing a Native TCR.

Authors:  Wingchi Leung; Helen E Heslop
Journal:  Cancer Immunol Res       Date:  2019-04       Impact factor: 11.151

Review 2.  Beyond conventional immune-checkpoint inhibition - novel immunotherapies for renal cell carcinoma.

Authors:  David A Braun; Ziad Bakouny; Laure Hirsch; Ronan Flippot; Eliezer M Van Allen; Catherine J Wu; Toni K Choueiri
Journal:  Nat Rev Clin Oncol       Date:  2021-01-12       Impact factor: 66.675

Review 3.  In Vitro-Transcribed mRNA Chimeric Antigen Receptor T Cell (IVT mRNA CAR T) Therapy in Hematologic and Solid Tumor Management: A Preclinical Update.

Authors:  Thangavelu Soundara Rajan; Agnese Gugliandolo; Placido Bramanti; Emanuela Mazzon
Journal:  Int J Mol Sci       Date:  2020-09-06       Impact factor: 5.923

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.